Oncology Medical News about myeloma bone disease;Bortezomib;Histone Deacetylase Inhibitor JNJ-26481585

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma
Cancer Research, 07/07/09

Deleu S et al. - In a study to investigate the effect of bortezomib alone or in combination with JNJ-26481585 on tumor burden, and multiple myeloma (MM) bone disease in the 5T2MM model, results indicate that this combination therapy could be a useful strategy for treatment of MM pts, especially in those with skeletal complications.

Methods

Injection of 5T2MM cells into C57Bl/KaLwRij mice resulted in MM bone disease, characterized by increase in the percentage osteoclasts, decrease in osteoblasts, trabecular bone volume, trabecular number, and development of bone lesions.

Results

Treatment of 5T2MM-bearing mice with bortezomib significantly reduced tumor burden, angiogenesis, and MM bone disease.
The combination of bortezomib with JNJ-26481585 resulted in a more pronounced reduction of osteoclasts and increase of osteoblasts, trabecular bone volume, and trabecular number vs bortezomib as single agent.
These data suggest that bortezomib has bone remodeling properties that can be improved in combination with low-dose JNJ-26481585.

<< Previous
Subcellular localization of cyclic AMP-responsive element binding...

Next >>
A "vascular normalization index" as potential mechanistic...

Mikuliczs disease with severe thrombocytopenia following autologous stem cell transplantation in a multiple myeloma patient
International Journal of Hematology, 10/30/09 Relevance Score: 79%

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial : The Lancet Oncology
The Lancet Oncology - Online First, 10/23/09 Relevance Score: 79%

Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells
British Journal of Haematology, 10/16/09 Relevance Score: 79%

Combined Histocompatibility Leukocyte Antigenmatched Donor Bone Marrow and Renal Transplantation for Multiple Myeloma With End Stage Renal Disease: the Induction of Allograft Tolerance Through Mixed Lymphohematopoietic Chimerism
Transplantation, 10/08/09 Relevance Score: 79%

Mesenchymal Stem Cells for Bone Repair and Metabolic Bone Diseases
Mayo Clinic Proceedings, 10/09/09 Relevance Score: 69%